Field of Science

Physics's PR problem: Moving beyond string theory and multiple universes

 I was reminded of this by a timely post by MJ at "Interfacial Digressions". As everyone knows, chemistry has a PR problem. Fear of "chemicals" runs rampant without context or qualification. In addition, unlike physics and biology, chemistry is not considered to be the science that answers profound questions about the origins of life or the future of the universe. Of course there's evidence to the contrary for each one of these thoughts - modern life would be impossible without chemistry and the origin of life can claim to be the ultimate grand chemical question - but it's been hard to convince the public of this truth. The acute PR problem for chemistry is illustrated by the fact that popular literature on chemistry does not sell half as well as that on physics; just count the number of chemistry versus physics books in your Barnes & Noble the next time you visit (if you are still obsessed with paper that is).

But I think physics also has a PR problem, and it's of a different kind than chemistry's. This statement should elicit gasps of indignation, since the Greenes, Hawkings and Kakus seem to be doing quite well; they are household names and every one of their books instantly gathers hundreds of positive reviews on Amazon. But there's still a problem and it's not one that is acknowledged by many of these leading popular expositors, at least partly because doing so would rob them of their next big NewYork Times bestseller and the accompanying profits. Look at the physics section in your B&N next time and you will understand what I am talking about.

The problem is that most of the popular physics that the public enjoys constitutes perhaps 10% of the research that physicists worldwide are engaged in. Again, count the number of physics books in your local bookstore, and you will notice that about 90% of them cover quantum mechanics, cosmology, particle physics and "theories of everything". You would be hard-pressed to find volumes on condensed matter physics, biophysics, the physics of "soft" matter like liquids and non-linear dynamics. And yes, these are bonafide fields of physics that have engaged physics's best minds for decades and which are as exciting as any other field of science. Yet if you ask physics-friendly laymen what cutting-edge physics is about, the answers will typically span the Big Bang, Higgs boson, black holes, dark matter, string theory and even time-travel. There will be scant mention if any of say spectroscopy, optics, polymers, magnetic resonance, lasers or even superconductivity.

Whether physicists admit it or not, this is a PR problem. Laymen are being exposed to what is an undoubtedly exciting but tiny fraction of the universe of physics research. For eager readers of the popular physics literature, the most exciting advances in physics are encapsulated between the Higgs boson and the Big Bang and that's all they think exists in heaven and earth. In my opinion this does a great disservice to the majority of physicists around the world who work on other, equally exciting topics. Just consider one major academic physics department, say Stanford, and you get an idea of the sheer variety of projects physicists work on. Physics books may still sell, but the physics they describe is something which most of the world's physicists don't do. I cannot see how this cannot be called a PR problem.

So who is responsible for this situation? Well, in one sense, nobody. The fact is that the public has always shown a taste for "big picture" topics like cosmology and quantum mechanics and physicists have been indulging this taste for quite a while now. And who can blame the public for being attracted to relativity with its time paradoxes or quantum mechanics with its cats and famous personal rivalries. Even in the 1920s, the popular physics literature sported the likes of Arthur Eddington and James Jeans who were pitching nuclear physics and relativity to packed audiences. The mantle was passed on in the postwar era to scientists like George Gamow and Isaac Asimov who spread the gospel with gusto. And the trend continues to the present day, with even a mind-numbingly well-trodden topic like the history of quantum theory finding eager expositors like Louisa Gilder, Manjit Kumar and David Lindley. All their books are highly engaging, but they are not doing a favor to other equally interesting branches of physics.

The popular physics literature has also started turning quasi-religious, and writers like Brian Greene and Michio Kaku are unfortunately responsible for this development. Greene in particular is a remarkably charismatic and clear writer and lecturer who has achieved almost rock-star status. Sadly, his popular expositions are seeming more like rock concerts rather than serious physics lectures. Part of the problem is his almost evangelical espousal of highly speculative, experimentally unverified (and perhaps even unverifiable) but deliciously tantalizing topics like string theory and multiple universe. Greene's books seem to indicate that the more speculative the topic, the more eagerly it will be assimilated by lay audiences. This cannot but be a disturbing trend, especially for those thousands of physicists whose research may sound pedestrian but which is also more solidly grounded in experiment and as interesting as perpetually splitting universes. One suspects that even the famous popular physics writers of lore like George Gamow would have been hesitant in pitching highly speculative topics merely for their "Wow" factor. If the biggest selling point of a popular physics book is its dependence on experimentally unverified ideas that sound more like science fiction, popular physics is in trouble indeed. 

In addition, whatever lacks the "Wow" factor seems to evidence the "Yawn" factor. By this I am referring to books constantly repackaging old wine in new bottles. A good example is Lisa Randall's latest book. It's an extremely well-written and spirited volume but it mostly treads the same tired ground of quantum mechanics, relativity and the Large Hadron Collider. The bottom line is that the popular physics literature seems to have reached a point of diminishing marginal returns. It's become very difficult to write anything on the subject that's either not well-trodden or highly speculative.

There is another unintentional effect of this literature which is more serious. Today's popular physics gives people the impression that the only questions worth addressing in physics are those that deal with unified theories or the birth and death of the cosmos. Everything else is either not worth doing or is at best done by second-rate minds or graduate students (take your pick). Not only does this paint a skewed picture of what's important and difficult in the field, it also inflates the importance and intellectual abilities of physicists working on fundamental problems at the expense of those working on more applied ones. This again does a great disservice to very many challenging problems in physics and the people addressing them. Building a room-temperature superconductor, understanding turbulence, designing new materials for capturing solar energy, keeping atoms stable at cold temperatures, kicking DNA around with lasers and of course, beating nuclear fusion at its own thermodynamic game are still long-unsolved problems that promise to engage the finest minds in the field. Yet the myth that the greatest problem in physics is finding the theory describing "everything" persists. This constant emphasis on "big" questions provides a biased view not just of physics but in fact of all of science, most of which involves solving interesting but modest problems. As MJ says in his post, most physicists he knows aren't really after 3 laws that describe 99% of the universe but would be content finding 99 laws that describe 3%. 

So what's the solution? As with other problems, the first step would be to acknowledge that there is indeed a problem. Sadly this would mean somewhat blunting the public's starry-eyed impression of cutting-edge physics, which the leading expositors of physics would perhaps be unwilling to do. At least some physicists might be basking in the public's mistaken grand impression that cosmology and quantum theory are all that physicists work on. If I were a soft condensed matter physicist and if I told someone at a cocktail party that I do physics, the images that response would evoke would most likely include long-haired professors, black holes, bosons and fermions, supernovae, nuclear weapons and time-travel. I may be excused for sounding hesitant to dispel this illusion and emphasize that I actually work on understanding the exact shape of coffee stains.

Nonetheless, this harsh assessment of reality might be necessary to cut the public's umbilical cord to the Hawkings, Greenes and Randalls. But this would have to be done by someone else and not by Brian Greene. Now let me make it clear that as speculative as I might find some of his proclamations, I don't blame Greene at all for doing what he does. You cannot fault him for not reminding the public about the wonders of graphene since that's not his business. His business is string theory, that's what he is passionate about, and nobody can doubt that he is exceedingly good at practicing this trade. Personally I have enjoyed his books, and in an age where ignorance of science seems to reach new lows, Greene's books provide at least some solace. But other physicists would have to tread into territory that he does not venture into if they want to solve physicists' PR problem. 

Gratifyingly some physicists have already started staking their claims in this territory, although until now their efforts have sounded more like tiptoeing and less like confident leaps. Nevertheless, James Gleick proved in the 1990s with his "Chaos" that one can indeed grab the public's attention and introduce them to an entirely new branch of science very successfully. In recent years this tradition has been carried on with varying degrees of success by other scientists, and they provide very promising examples of how the PR problem could be addressed. Let me offer a few suggestions. Robert Laughlin has talked about emergence and condensed matter in his "A Different Universe". David Deutsch has laid out some very deep thoughts in his two books, most recently in "The Beginning of Infinity". Philip Anderson expounds on a variety of interesting topics in his recent collection of essays. And while not entirely about physics, Stuart Kauffman's books have done a great job at dismantling the strong reductionist ethic endemic in physics and suggesting new directions for inquiry. The common emphasis of these authors is on emergent, complex, adaptive systems, a paradigm of endless opportunities and questions which has been generally neglected by the popular physics literature. In addition there are excellent, courageous critiques of string theory from Peter Woit and Lee Smolin that deviate from the beaten track.

Sadly most of these books, while exceedingly interesting, are not as engagingly written as those by Greene or Randall. But the modest success they have enjoyed seems to indicate that the public does have a taste for other areas of physics as long as they are described with verve, passion and clarity. Maybe someday someone will do the same for turbulence, DNA dynamics, non-Newtonian liquids and single-molecule spectroscopy. Then physics will finally be complete, at least in a popular sense.

Image source

Striking Alzheimer's before it strikes

Those following the news on trials of drugs against Alzheimer's disease must be familiar with the depressing outlook from the front lines. There was a string of failures reported in the last few years for therapies intended to disrupt the beta amyloid protein in AD. The failures have sent researchers back to the drawing board and the beta amyloid hypothesis itself has been strongly questioned. Amyloid is almost certainly involved in some big way with the disease, but its exact role as a causative agent has been under scrutiny for a while now.

Several factors could be responsible for the failure of these trials, but one factor in particular was bandied about as an obvious one; perhaps the intervention came too late to help the patients. We now know that diseases like AD and cancer often kick in quite early when they are beyond the detection limit of current diagnostic techniques. Perhaps, the thinking goes, we might stand a chance of beating the disease if we intervene early enough.

This thinking is completely sound, except for the problem that there is even now no definitive test to detect AD at very early stages. Fortunately for scientists - and quite certainly unfortunately for those unlucky enough to draw from this lottery - there are certain populations which are genetically predisposed to the disease. Members of these families typically get the disease in their 40s and by the 50s they are completely debilitated by it. The most prominent of these groups is an unfortunate family in Colombia, and the New York Times reported on them in 2010.

Now the Times reports on a drug trial designed to test the early intervention hypothesis in this clan. The drug in question is an antibody targeted against amyloid called crenezumab. The antibody was developed by Genentech and the preventative study is being jointly funded by the company, the NIH and a private foundation. Naturally it's going to be a long-drawn project; suspected patients are going to be started on the treatment when they are as young as 30, and their progress will be monitored meticulously over the next several years through both diagnostic mental tests and non-invasive techniques like PET scans.

This is a very hopeful and well thought-out experiment, and just like Derek who blogged about this today, I wish both the patients and the researchers the very best. Sadly, the history of the AD trials cited above does not fill me with too much hope. The amyloid hypothesis has constantly been under attack for the last decade or so. The most significant discovery in this regard was the finding that small oligomers of the protein rather than the full misfolded form might be the real culprit; but crenezumab seems to function by attacking the full form.

More intriguing and disturbing are the potential consequences for the normal health of the patients. Amyloid is definitely part of the normal functioning of the human body but nobody knows its exact function yet. However, it seems clear that the misfolded and normal soluble form of the protein are in some kind of equilibrium with each other. More interestingly, recent reports have implicated amyloid as an antibacterial agent. There's also some longstanding studies that suggest that amyloid forms free radicals which are usually toxic, but which may also help kill bacteria. I myself had speculated on amyloid's possible evolutionary role as a defense mechanism.

All this makes me skeptical about disturbing the normal vs misfolded amyloid equilibrium as a long-term strategy; the process may well be a crucial one, and killing the messenger might kill the message. Everyone wants this trial to succeed but we probably shouldn't be surprised if something disappointing shows up. One thing's for sure; this stuff will generate a lot of data, and that's what science is about.
Image source

John LaMattina on the new NIH drug discovery center

There's a post by ex-Pfizer research chief John LaMattina about the new NIH drug discovery center, and predictably he does not seem too happy about it. While the initial center was supposed to be all about translational research, the latest idea is to use the NIH's resources for "repurposing", or discovering new indications for old drugs.

LaMattina echoes some of the dissatisfaction that a few of us have earlier expressed about this idea. The main point here is that the NIH should not be in the business of discovering new drugs; it should be in the business of doing the basic biological research that may enable such potential discoveries. In fact one might argue that the biggest challenge facing drug discovery today is an incomplete understanding of the complexities of the biology underlying major diseases. Just think of the conflicting data and the complications that have emerged from attacking beta amyloid in Alzheimer's disease for instance. There's hardly any doubt that better treatments can only result from a proper evaluation of the basic biology of disease. And it's also clear that this understanding is not going to come from industry. Only the NIH and academic labs can accomplish this, and spending money on therapies when it could more fruitfully be spent on such fundamental studies seems to be folly. So ironically, funding drug discovery may hinder an understanding of the very foundations that may truly enable it.

Nor is what the NIH doing truly novel. As LaMattina points out, repurposing is an obvious route and an attractive one at that, since finding a novel indication for an old drug means that the drug has already run the gauntlet of FDA approval. So we can bet that industry would have worked on repurposing if they could possibly do it. Now granted, there's always going to be compounds that were dropped for financial or project-related reasons which may be potentially valuable agents for all kinds of conditions. And we can also assume that these numbers might have grown during the last few years when projects have been axed and personnel laid off in increasing numbers. But what are the chances that hidden among those dusty vials on the shelf is the next cure for pancreatic cancer? Of course one may never find out if one does not look, but the NIH's announcements make it sound like there's pure gold among those neglected compounds, waiting to be discovered. The fact is that examples of truly repurposed drugs are quite few; as LaMattina points out, even the two repurposed drugs cited by NIH director Francis Collins are drugs for which the "other" indications were rather obvious based on their mechanism of action. Repurposing by itself is not entirely misguided, but repurposing at the cost of basic biomedical research draws resources away from more worthy endeavors.

Thus, by and large LaMattina's arguments seem to be cogent. Unfortunately the indignation on the other side of the equation is not as justified as it sounds. LaMattina refers to a statement by legendary Merck ex-CEO Roy Vagelos along the lines that if there was real benefit to something that the NIH wants to do, pharma would already be doing it. Sadly this is increasingly not the case. In the last few years pharma has defined "benefit" based on whether something's going to affect the next quarter's profits. Working on Alzheimer's disease and other CNS disorders where the rewards are long-term but undoubtedly stellar is no longer considered a beneficial strategy. So we have a situation here where industry is rightly advising the NIH to work on basic research rather than drug development, but not committing itself to its part of the deal. As well-intended as it may be, the impact of your advice gets blunted a little if you stop looking in the mirror.

A history of metallocenes: Bringing on the hashish

Following on the heels of the comprehensive article on metal-catalyzed reactions noted by Derek, here's another one by Helmut Werner specifically about the history of ferrocene and other metallocenes. It's got lots of interesting trivia about priorities, personalities and chemical developments. The article traces early priority disputes in the discovery of ferrocene followed by an account of the rush to explore other metal-organic systems.

It's hard for us today to imagine the shock that was felt on witnessing the existence of the first sandwich compound, a complex of iron sandwiched between two cyclopentadienyl rings. Before ferrocene the division of chemistry into inorganic (especially metallic) and organic compounds was assumed to be virtually set in stone, and this was one of those classic developments that shatters the mirror between two realms. The world of transition metal-mediated chemistry that the discovery inaugurated completely transformed the academic and industrial practice of chemistry, led to several Nobel Prizes and turned out to be one of the most beneficial scientific developments of the latter half of the twentieth century. 

The novelty of the new compound is best captured by what must surely be the most memorable reply sent by a journal editor to a submitting author, this one being from Marshall Gates (the editor of JACS) to R. B. Woodward:

"We have dispatched your communication to the printer but I cannot help feeling that you have been at the hashish again. 'Remarkable' seems a pallid word with which to describe this substance"

Perhaps the most extraordinary part of the story is the candid and rather dramatic note from Woodward to the Nobel committee lamenting his exclusion from the 1973 Nobel Prize awarded to Geoffrey Wilkinson and Ernst Fischer.

"The notice in The Times of London (October 24, p. 5) of the award of this year's Nobel Prize in Chemistry leaves me no choice but to let you know, most respectfully, that you have - inadvertently, I am sure - committed a grave injustice"

Woodward went on to rather pointedly emphasize his individual contributions to the discovery, making it sound like he had done Wilkinson at least a minor favor by putting his own name last on the manuscript. 

"The problem is that there were two seminal ideas in this field-first the proposal of the unusual and hitherto unknown sandwich structure, and second, the prediction that such structures would display unusual, "aromatic" characteristics. Both of these concepts were simply, completely, and entirely mine, and mine alone. Indeed, when I, as a gesture to a friend and junior colleague interested in organo-metallic  chemistry, invited Professor Wilkinson to join me and my colleagues in the simple experiments which verified my structure proposal, his initial reaction to my views was close to derision . . . . But in the event, he had second thoughts about his initial scoffing view of my structural proposal and its consequences, and all together we published the initial seminal communication that was written by me. The decision to place my name last in the roster of authors was made, by me alone, again as a courtesy to a junior staff colleague of independent status".

Interestingly, his recollection almost completely differs from that of Wilkinson's who stated in a 1975 review that he thought of the structure right away while Woodward immediately started thinking about its reactions. It's intriguing - and probably futile - to psychoanalyze the reasons for this very public expression of disappointment, especially coming from one who was not exactly known for publicly airing his personal feelings (for instance, his Cope Award lecture is the only time Woodward really provided personal biographical details). By 1973 Woodward had already won the Nobel Prize, and while he was always known to be extraordinarily ambitious, he must have known that his place in chemical history had already been secured; at that point he had even published the landmark papers on the Woodward-Hoffmann rules. Perhaps he sincerely felt that he deserved a share of the prize; nevertheless, it's a little curious that such a towering figure in the field made it a point to convey his disappointment at not winning a prize so publicly and strongly. Whatever the reason, Woodward's note makes it clear that scientists - both famous ones and otherwise - are keen to stake their priority. They are after all human.

To be fair to the prize committee, the award was given for the more general field of organometallic chemistry that the discovery of ferrocene launched rather than for the structure of ferrocene itself. Even at the beginning Wilkinson had been more interested in the new structural class of metallocenes while Woodward had been more interested in the kind of reactions the novel compounds would undergo. After the initial finding, while Wilkinson immersed himself in investigating the interactions of other metals with similar organic systems, Woodward went back to his life's love; the chemistry of natural products. Thus, it seems sensible in retrospect to have the prize given to Wilkinson and Fischer if the purpose had been to honor a new field of chemistry. Woodward died in 1979, and I am not familiar with his later thoughts on the subject if he had any. But of course, his place in the annals of science had long been assured, and ferrocene has turned into little more than an interesting historical footnote in his list of superlative achievements.

Note: The quotes by Woodward come from an article by Thomas Zydowsky from the Northeastern Section of the ACS that I had noted in the mailing list ORGLIST...in 2001. Time flies.

The devil under the hood: To look or not to look?

Modern biology and chemistry would be unthinkable without the array of instrumental techniques at their disposal; indeed, one can make a case that it was new methods (think NMR, x-ray crystallography, PCR) rather than new concepts that were really responsible for revolutions in these disciplines. The difference between a good paper and a great paper is sometimes the foolproof confirmation of a decisive concept, often made possible only by the application of a novel technique.

Yet the onslaught of these methods have brought with them the burden of responsibility. Ironically, increasing user-friendliness of the tools has only exacerbated this burden. Today it's all too easy to press a button and communicate a result which may be utter nonsense. In a recent article in Nature titled "Research tools: Understand how it works", Daniel Piston from Vanderbilt laments the fact that many modern instruments and techniques have turned into black boxes that are being used by students and researchers without an adequate understanding of how they work. While acknowledging the undoubted benefits that automation has brought to the research enterprise, Piston points out the flip side:

Unfortunately, this scenario is becoming all too common in many fields of science: researchers, particularly those in training, use commercial or even lab-built automated tools inappropriately because they have never been taught the details about how they work. Twenty years ago, a scientist wanting to computerize a procedure had to write his or her own program, which forced them to understand every detail. If using a microscope, he or she had to know how to make every adjustment. Today, however, biological science is replete with tools that allow young scientists simply to press a button, send off samples or plug in data — and have a result pop out. There are even high-throughput plate-readers that e-mail the results to the researcher.

Indeed, and as a molecular modeler I can empathize, since modeling presents a classic example of black-box versus nuts-and-bolts approaches. On one hand you have the veteran programmers who did quantum chemistry on punch cards, and on the other hand you have application scientists like me who are much more competent at looking at molecular structures than at code (you also have those who can do both, but these are the chosen few). There's a classic time spent vs benefits accrued tradeoff here. In the old days (which in modeling lingo go back only fifteen years or so), most researchers wrote their own programs, compiled and debugged them and tested them rigorously on test systems. While this may seem like the ideal training environment, the fact is that in modern research environments and especially in an industry like the pharmaceutical industry, this kind of from-scratch methodology development is often just not possible because of time constraints. If you are a modeler in a biotech or pharma company, your overlords rightly want you to apply existing software to discover new drugs, not spend most of your time writing it. In addition, many modelers (especially in this era of user-friendly software) don't have strong programming skills. So it's considered far better to pay a hefty check to a company like Schrodinger or OpenEye who have the resources to spend all their time perfecting such programs. 

The flip side of this however is that most of the software coming from these companies is not going to be customized for your particular problem, and you can start counting the number of ways in which a small change between training and test sets can dramatically impact your results. The only way to truly make these programs work for you is to look under the hood, change the code at the source and reconfigure the software for your unique situation. Unfortunately this runs into the problem stated above, namely the lack of personnel, resources and time for doing that kind of thing.

So how do you solve this problem? The solution is not simple, but the author hints at one possible approach when he suggests providing more graduate-level opportunities to learn the foundations of the techniques. For a field like molecular modeling, there are still very few formal courses available in universities. Implementing such courses will give students a head-start in learning about the relevant background, so that they can come to industry at least reasonably well-versed with the foundations and subsequently spent their time actually applying the background instead of acquiring it. 

The same principal applies to more standard techniques like NMR and x-ray diffraction. For instance, even today most courses in NMR start with a basic overview of the technique followed by dozens of problems in structure determination. This is good training for a synthetic chemist, but what would be really useful is a judiciously chosen list of case studies from the current literature which illustrate the promises and pitfalls of magnetic resonance. These case studies would illustrate the application of NMR to messy, real-world problems rather than ideal cases. And it's only by studying these case studies that students can get a real feel for the kind of problems for which NMR is really the best technique.

Thus, gaining a background in the foundations of a particular technique is only one aspect of the problem, and one which in fact does not sound as important to me as getting to know the strengths and limitations of the technique. To me it's not as important to formally learn quantum chemistry as it is to get a feel for the kinds of systems for which it works. In addition you want to know what the results really mean, since the numbers you get from the output are often more or less informative than they look. Learning the details of perturbation theory is not as key as knowing when to apply it. If the latter is your goal, it may be far more fruitful to scour the literature and get a feel for the circumstances in which the chosen technique works rather than just take formal classes. And conveying this feel for strengths and limitations of techniques is again something we are not doing very well in graduate school, which we should be.

Nanopore sequencing: The next big thing?

The biotech field is abuzz with nanopore sequencing, with lots of people starting to think it might be the Next Big Thing. And not just one of those incremental developments that keep science humming along, but more along the lines of Kuhn's paradigm shifts. The belief is that nanopore sequencing may finally lead to the domestication of biotechnology, which will open up brave new worlds in all kinds of domains like drug development, law and health insurance. The ultimate manifestation of this technology, of which Oxford Nanopore Technologies is the leader, is a flash drive that can be plugged into your computer and which can sequence your DNA for about 1000$ within a day or two. Personal genomics does not get any more well-defined than that.

There's an article on nanopores in this week's Science which lays out both the promises and the challenges. Nanopore sequencing seems to be one of those disarmingly simple ideas which had to be hammered out into practice by sweating all the details. About half a dozen people, starting with David Deamer at UCSC, contributed to the basic concept which sounds simple enough; find a pore with an electrical current flowing through it and thread a DNA strand through the pore. The expectation is that as each base of the DNA passes through, there will be a small, characteristic change in the ionic current. The great hope is that this change would be unique for each one of the four bases, thus allowing you to read the sequence.

As usual, the implementation of the idea faced major hurdles. For one thing, nobody knew of a pore that would allow DNA to thread through it until Deamer heard of alpha-hemolysin, a protein with a magnificent structure that is used by some bacteria to break down red blood cells by literally drilling holes in them. Deamer realized that the perfectly positioned inner channel of hemolysin could be used to string DNA through it. After this initial breakthrough, the main problem remained reducing both the number and the speed of the base pairs enough to read them accurately. The first problem was resolved through the discovery of another protein called MspA which has a pore narrow enough to allow just four base pairs through at any given moment. The negatively charged residues inside the channel had to be removed through mutations to prevent repulsion with the negatively charged DNA. The second problem was addressed by using a special DNA polymerase to hold the DNA on top of the hemolysin and create a bottleneck.

The culmination of all these efforts was a publication two months back in which they could distinguish and sequence DNA strands ranging from 42 to 53 bases in length. That's a good start, but of course it's a trivial number compared to most respectable genomes of interest. And this is where the skeptics start chiming in. The error rate of the sequencing is currently 4%, mostly engendered by stalled DNA polymerase and bases that slip past without being read. For the three billion base pairs of the human genome, this will translate to about 120 million bases read incorrectly. That's a staggering number, especially if you consider that many genetic disorders arise from changes in a single base pair. When you are dealing with complex disorders in which small changes in sequence mean the difference between health and disease, this kind of accuracy may just not be good enough. And of course, that's assuming that such minor changes in sequence are truly meaningful, but that's a different story. In addition there are probably going to be problems associated with the durability of the pore, not to mention the usual challenges involved in mass producing such a technology. I am assuming the midnight oil at Oxford is being burnt as we speak.

So nanopore sequencing may well be the next big disruptive technology. But its actual impact can only be judged after they iron out these key wrinkles and publish a few papers dealing with typical-sized genomes. Until then, cautious optimism without strenuous limb-flailing would be the correct response.

Image source

Woodward on how to travel incognito

Searching aimlessly for material on R. B. Woodward online, I came across an amusing source: "Droll Science" by Robert Weber. In it I found the following droll anecdote:

At the Munich (1955) meeting of the Gesellschaft deutscher Chemiker, Woodward attracted attention as he roamed the halls carrying a big notebook in a blue silk cover on which was embroidered the structural formula of strychnine. The next day he appeared bearing a cover innocent of any embroidery. Asked a friend, "Why no structural formula?" Quipped Woodward, "Oh, I'm traveling incognito today."

The anecdote probably says more about the man than it intends to: Woodward's identity was inextricably linked to the objects of his creation, and without them, he could indeed pronounce himself incognito.

Using gas-phase conformations to predict membrane permeability of drugs

Drug discovery is a complex process in which multiple factors need to be optimized. One of the most important stages involves maximizing the cell permeability of compounds, since even the most potent molecule is worth nothing if it can't get into cells. A particularly intriguing challenge in this regard is to explain how nature has solved this problem by engineering natural products featuring "non Rule of 5" compounds- typically large, greasy molecules with several hydrogen bonding groups - acting as drugs. Nature seems to have overcome chemists' queasiness at making such compounds, and it's worth noting what lessons we can learn from her. Among other challenges, one has to get these drugs across lipid-rich cell membranes, and predicting this membrane permeability could be a very useful thing. One clever strategy that nature has adopted to do this is to fold up the molecule through lots of internal hydrogen bonds, thus minimizing its polar surface area and allowing it to be stable in the membrane.

Naturally it would be quite useful to be able to theoretically predict beforehand which compounds will form such hydrogen bonds, and there have been a few papers taking a stab at this goal. Here's one such paper from a group at Pfizer which stuck out for me because of its simplicity. In it the author look at three apparently non-druglike compounds- cyclosporin (an immunosuppressant), atazanavir (an antiviral) and aliskiren (an anti hypertensive) and try to the theoretically account for their observed permeabilities.

 What they do is run conformational searches on these compounds in the gas phase (or in "vacuum", if that suits your anti-Aristotlean sentiments) and look at the low energy conformations. In two of the three cases the low-energy conformations present lots of intramolecular hydrogen bonds, and the authors say that this is consistent with the stabilization of the drug inside the membrane, account for its known high permeability and oral bioavailability. They also verify these hydrogen bonds through NMR in non-polar solvents which are supposed to simulate the lipid membrane. For the third compound, aliskiren, they observe only two groups hydrogen bonded in the gas phase and they think this is consistent with the compound's low permeability. The paper's conclusion is that the presence of hydrogen-bonded conformations in the gas phase is a fair predictor of favorable permeability.


The study seems like an interesting starting point but I am skeptical. For starters, I have run more than my share of gas-phase conformational searches over the years and the one ubiquitous observation is that most polar, druglike compounds show "collapsed" conformations, with hydrogen bonding groups tightly interlocked. The main reason is that these calculations are carried out in vacuum, where there is no intervening solvent to shield the groups from each other. Coulomb's Law runs rampant in these situations, and a proliferation of collapsed, highly hydrogen-bonded conformations are a headache for any conformational search. So I am not surprised that the authors see all these hydrogen bonds. Sure, they say they don't see them for aliskiren, but even aliskiren demonstrates two so I am not sure how to interpret this conclusion.

The other important thing is that what matters for membrane permeability is not just whether an internally hydrogen bonded conformation is present in a nonpolar medium, but whether the desolvation penalty to achieve that conformation from the initial panoply of conformations in water is easily overcome. It's hard to draw a conclusion about a favorable membrane conformation of a drug unless there is an estimate of the desolvation penalty. At the very least the authors should have carried out a conformational analysis in water to get a crude estimate. In contrast, another study trying to calculate the permeability of peptides seemed to take this factor into account.

Lastly of course, the paper looks at only three cases. A much larger dataset will have to be examined in order to predict any correlations between hydrogen-bonded gas-phase conformations and membrane permeability. But while I am not sure the recent paper comes up with a general principle to do this, it's clear that conformational analyses of this kind (preferably in water, chloroform and the gas phase) will help. Understanding how nature has managed to engineer permeable, bioavailable beasts like cyclosporine is an important enough goal to benefit from such approaches.

The anatomy of peer review: Why airing dirty laundry in public is important

Since everyone is talking about Ron Breslow, I thought I might bring readers' attention to a truly fascinating (from the point of view of the sociology of science) article published in Nature in 1992 regarding two of Breslow's papers. The article was written by Prof. Fred Menger (Emory) and Prof. Albert Haim (Stony Brook) and details what happened when the two tried to publish a rebuttal addressing errors in two Breslow articles from the Journal of the American Chemical Society (JACS).

First I want to emphasize the reason why I am writing about this episode. I write about it not because I want to add to Breslow's troubles. I don't want it to sound like I am kicking someone when they are down, nor do I think that I will ever have the capability to do this to someone like Breslow. As I have reiterated in other places, neither this account nor the recent controversy should blind us to an unambiguous fact; Breslow's contributions to research, service and education have been outstanding by any standards. Most scientists would be lucky if they could accomplish half of what he has done during an unusually long and productive career that has still not slowed down. We can all hope that people will continue to remember him by his superlative accomplishments.

So I am not writing this post because I want to add to further criticism of Breslow. It's because I have always thought that the Nature article is a unique document in the history and sociology of chemistry, a great illustration of the pitfalls and promises of peer review that deserves a wider audience. I think laymen (who don't have journal access) will find its contents very interesting, and there's lessons in there for fellow scientists too. I do want to add a disclaimer: Prof. Menger was on my Ph.D. committee and I have enormous respect for his research, but as someone interested in the way science functions, this paper would have been equally fascinating to me even if I had absolutely no connection to him. There were several other papers related to this incident, but the one in Nature stands out as a unique example of scrutiny.

The article is one of the most remarkable publications I have ever read, for two reasons. Firstly, because it presents a rare glimpse into what we might call the "anatomy" of peer review; and it does this in excruciating detail, with warts and all exposed. Secondly, because it makes you wonder whether a journal like Nature would ever again have the inclination to publish something like this.

The whole episode germinated when Breslow and a pair of graduate students (Eric Anslyn and Deeng-Lih Huang) published two papers in JACS dealing with the kinetics of an imidazole-catalysed nucleotide cleavage reaction. This is standard stuff in physical organic and bioorganic chemistry and is part of a large body of work going back 50 years. What was interesting was that the authors seemed to derive negative rate constants for some of the reactions. Now, even college students will recognize this as odd; a rate constant is supposed to indicate the speed of a reaction. If it's positive, the reaction proceeds. If it's zero, the reaction halts. But what is a negative rate constant supposed to mean? Of course the original authors had their own interpretation of their numbers. Independently, Menger and Haim investigated this question and they found out a few rather significant problems with the two papers. The technical details can only be appreciated by a physical organic chemist, but the main problem seemed to be in treating the background reactions with water in the absence of imidazole. It seemed that at least some of the "negative" rate constants were artifacts of the data fitting.

The publication saga started when Menger and Haim independently submitted papers to JACS criticizing the original paper and offering corrections. The editor of JACS at the time was Alan Bard, an internationally renowned chemist who served a distinguished stint as journal editor for several years. Menger's paper was rejected by the reviewers with some odd and rather self-contradictory commentary. On one hand, the reviewers acknowledged the errors in the Breslow papers, but on the other hand they inexplicably chose to reject the manuscript, "hoping" that Breslow and Huang would publish a more detailed explanation and correction. It wasn't clear why they would not let Menger himself publish a correction in the journal.

Haim's paper was also rejected by the journal with similar comments. At this point both Menger and Haim wrote to Bard and the associate editor in charge of the manuscripts. They appealed to JACS's editorial policy which encouraged the submission of manuscripts detailing major errors in published material. This appeal did not have much effect. Something strange also transpired at this juncture; as Menger details, Breslow sent a rather interesting note to Haim, saying: "I don't know what you are so excited about. Are you being led astray by a notoriously unstable individual?". 

Following their unsuccessful attempt at publication in JACS, both Menger and Haim did what scientists always do; try to publish in other places. Haim first send his manuscript to the Journal of Physical Chemistry (JPC). JPC's response was about as strange as JACS's; while acknowledging the problems with the original papers, they too chose not to publish Haim's manuscript. Menger in turn sent his paper to the Journal of Organic Chemistry (JOC). He seems to have found a much more sympathetic audience in the journal's chief and associate editors, Clayton Heathcock and Andrew Streitwieser, both leading researchers. The paper was accepted without much ado by Streitwieser who wondered how the original paper had made it past the JACS referees.

The story does not end there. Menger's JOC paper stimulated a number of largely favorable responses. An especially noteworthy response was from a Nobel Laureate, who sent a note to Bard saying, 

"It seems to me there is a long-established scientific etiquette which says that papers pointing out errors should be published in the same journal in which the original article appeared". 

But these encouraging exchanges were followed by a few calls for retraction of the JOC paper, one of these being from Breslow. At least some of these raised legitimate scientific questions. This prompted Heathcock to ask for clarification, which Menger duly provided. Streitwieser accepted Menger's responses and the paper was published. To the journal's credit, they even permitted a footnote in which Menger said that his attempts to publish his paper in JACS had been rejected.

Meanwhile, Haim was still trying to publish his correction in JACS. He sent a revised, more thorough manuscript to Bard, asking that the original associate editor who had rejected the manuscript be replaced by a fresh pair of eyes. Bard did not agree to this request, but asked Haim to recommend ten referees for the paper. The article was sent to four of these reviewers. Two of the reviewers again agreed that the original science contained errors but again asked that Breslow and his collaborators be given a chance to publish corrections. One reviewer's response was especially interesting; he or she thought that the matter should simply be dropped, ostensibly to protect the reputation of the author:
"It could lead to a reputation, rightly or wrongly, of the author being a nitpicker and Breslow would certainly fight back loudly. Who needs such things"

I find the part about being a nitpicker especially interesting. Firstly, the criticism was not just about a few minor details; it was about rather fundamental analyses and conclusions in the paper. But more importantly, a lot of science in fact is nitpicking because it's through nitpicking that one often uncovers the really important things. Science especially should provide a welcome refuge for nitpickers. 

In any case, after yet another rejection, Haim submitted another revised manuscript. It's worth noting that most reviewers' comments during the 11 months that Haim had tried to get his manuscript published had been favorable, and nobody had ever called Haim's basic analysis into serious question. Yet the paper kept on getting rejected for various reasons. Finally, Haim appealed to Bard and the paper suddenly and inexplicably got published.

Menger ends his account of the long saga with the following words:

"As the dust settles, it is comforting to reflect that the system ultimately worked. After all, both of us succeeded in getting our papers published. Yet this was accomplished only at the cost of considerable anguish to us. Few people, we presume, would be willing to go through this experience...Two problems are involved here. First is the mishandling of the original publications, which many people have come to regard as substandard. The second is the position taken by the associate editor after flaws were pointed out. That position can only be described as evasive and defensive. Without attributing motivation for his actions, we simply state that we believe them to have been inimical to the best interests of science"

He ends by hoping that the fear of open criticism would encourage scientists to police themselves better (At this point science bloggers should let out a collective hurrah, for reasons that will become apparent below). There is a postscript: Breslow replied to this lengthy report shortly (and gratifyingly, his response was published in the same journal) and described experiments that would clarify his earlier work, but he did not address the many questions about peer review raised in Menger's communication.

This fascinating account raises many important issues. For one thing, it was quite clear that the original paper had problems; even the reviewers consistently agreed with this part of the story. Thus the science seems pretty clear, and the ambiguity in the situation came from the human element. We will never know what went behind the scenes when the manuscripts were rejected even after the reviewers agreed with the rebuttal. Unfortunately motivations are hard to unravel, but one cannot help but suspect that there was prestige and influence at work here which thwarted efficient and open scientific revision. The fact that powerful people from the chemistry community (especially Breslow and Bard) were involved cannot be an inconsequential factor.

Secondly, it does seem important to me (although this is a relatively minor issue in my mind) for journals to publish corrections to papers in their own pages; at the very least, this underscores a culture of responsibility on the part of the journal and sends out a positive message. However this practice involves some interesting operational questions. Should the journal first allow the original authors to publish a correction? If so, how long should it wait before doing this? It seems clear to me that legitimate corrections should immediately be published, irrespective of the source.

The most remarkable fact about this account is that Nature published it, and in writing it Menger performed a unique and valuable public service. Personally I have never seen such a detailed dissection of peer review described in a major journal. Some people would deplore this public airing of dirty laundry. They would say that none of this can undo what happened, and the only effect of such articles is bad blood and destroyed reputations. I happen to disagree. I think journals should occasionally publish such analyses, because it alerts us to the very human aspect of science. It demonstrates to the public what science is truly like, how scientists can make mistakes, and how they can react when they are corrected or challenged. It sheds important light on the limitations of the peer review process, but also reaffirms faith in its ultimately self-correcting nature. Some people might think that this is a great example of how peer review should not be, but I would like to think that this is in fact exactly how the process works in the vast majority of cases; imperfect, ambiguous, influenced by human factors like reputations, biases and beliefs. If we want to understand science, we need to acknowledge its true workings instead of trying to fit it into our idealized worldview of perfect peer review.

In this day and age, blogs are performing the exact same function as Nature did in 1992, and this is clearly apparent from the latest Breslow brouhaha. Menger and Haim in 2012 would not have to test their patience by trying to publish in JACS for 11 months; instead they could upload their correction on a website and let the wonder of instant online dissemination work its magic. Blogs may not yet be as respectable as JACS, but the recent incident shows that they can be perfectly respectable outlets of criticism as long as the criticism is fair and rigorous. The growing ascendancy of blogs and their capacity to inflict instant harm on sloppy or unscrupulous science should hopefully result in much better self-policing, leading authors to be more careful about what they publish in "more respectable" venues. Thus, quite paradoxically, blogs could lead to the publication of better science in the very official sources which have largely neglected them until now. This would be a delightful irony.

Perhaps the greatest message that the public can take home from such incidents is that even great scientists can make mistakes and remain great scientists, and that science continues to progress in one way or another. No matter how bad this kind of stuff sounds, it's actually business as usual for the scientific process, and there's nothing wrong with it.

Would Ron Breslow's dinosaurs be typing this post?

Much has been written about a recent perspective in JACS written by Ronald Breslow on the origin of homochirality during the origin of life. There's excellent commentary on the topic from See Arr Oh and Paul@Chembark. Briefly, Breslow's paper describes some pretty interesting research from his and other groups establishing a possible mechanism for the transfer of chirality from alpha-methyl amino acids to standard amino acids, followed by the amplification of that small chirality excess through a variety of plausible mechanisms involving the concentration of the dominant enantiomer.

The paper would have remained an interesting chemistry curiosity about the origin of life. It could have even served to remind the public that the origin of life is chemistry's Big Question, had it not been for two lines at the end of the piece:

"An implication of this work is that elsewhere in the universe there could exist life forms based on D amino acids and L sugars...Such life forms could even be advanced versions of dinosaurs,  if mammals did not have the good fortune to have the dinosaurs wiped out by an asteroidal collision, as on Earth. We would be better off not meeting them."

What was interesting was that when I first came across the paper, I spent about two seconds on this line and moved on. The line is an amusing attempt at humor. You usually don't see humor in a technical paper, but in fact I am all for it; I think we need to spice up our otherwise dry scientific literature with the occasional joke. The content of the paper obviously had nothing to do with dinosaurs; it was about a specific technical chemical puzzle in the origins of life. And nothing would have come out of it had not the ACS PR office created a sensationalized news piece wrongly centered around these two lines. Scant attention was paid to the scientific substance of the paper, and it didn't help when other popular venues like The Huffington Post also questioned Breslow about it and received the following answer:

"From there, Breslow makes the jump to advanced dinosaurs. But why might extraterrestrial life be in that form? “Because mammals survived and became us only because the dinosaurs were wiped out by an asteroid, so on a planet similar to ours without the asteroid collision it is unlikely that human types would be there, more probably advanced lizards (dinosaurs),” Dr. Breslow told The Huffington Post in an email."

This set of events led to some unfortunate consequences. For one thing, the undue emphasis on dinosaurs at the expense of homochirality was another nail in the coffin of the public communication of chemistry. Here was a chance to explain to the public why the origin of life is chemically fascinating, but instead the chemical substance got overwhelmed by the precipitate of publicity surrounding dinosaurs. If the ACS is wondering why chemistry is having such a PR problem, now would be the time to look in the mirror.

The situation was exacerbated by more serious matters. Following a tip from some commentators, Stu Cantrill of Nature Chemistry looked up two old Breslow papers on the same topic and found out an extreme case of self-plagiarism; most of the paper seems to have been copied verbatim from the other sources. Breslow should not be blamed for inserting that little joke at the end - it was the media which sensationalized it - but he cannot be excused for the gratuitous self-plagiarism.

That's about what I want to say about this unfortunate episode since others have extensively covered it, but I do want to focus on Breslow's reply to The Huffington Post. Some have chided him for it, but the statement is actually not as absurd as it sounds since Breslow is asking a famous, age-old question in evolutionary theory: If the tape of evolution were re-run, would it again produce dinosaurs, Breslow and ACS editors? Or in other words, how predetermined is evolution, and how dependent is it on accidents? This question is a profound one , since if the answer is even an affirmative "yes", it has serious implications for not just science but for theology and philosophy and the whole puzzle of human existence. 

Stephen Jay Gould was a powerful advocate of contingency in evolution, and his argument is not surprising to see. Evolution has been shaped by so many quirks of environment and the fate of individual organisms and species, that it would be naive to think that chance did not play a role in it. A single piece of wood accidentally drifting apart and carrying a few species on it to an isolated island can sculpt the evolution of that species. And we know for a fact that more massive events like volcanoes and earthquakes certainly did this. In fact it was geologist Charles Lyell's descriptions of such seismic events that started Darwin down the path to evolution and natural selection. It seems thus that if one could hypothetically run "what if" scenarios, it's very unlikely that anything approximating modern humans and dinosaurs could ever arise.

But this answer is not as obvious as it sounds. The biologist Simon Conway Morris has put forth a competing scenario in which certain universal features of evolution guarantee the presence of common adaptations during the evolution of species. This argument is based on what's called "convergent evolution" which essentially refers to the existence of common solutions to diverse evolutionary problems. A typical example would be all kinds of mammals, fish, amphibians and reptiles whose bodies are adapted to swimming. In most of these creatures you see similarly shaped, streamlined bodies, muscles and bones which are suited for swimming. Another principle concerns homologous structures (and not convergent evolution, as a commentator reminded me) like the digits of the hand, whose basic plan seems to be conserved across species. Indeed, homologous evolution provide some of the strongest pieces of evidence for common evolutionary origins. Thus Morris's argument is that even if the evolutionary tape were to run again, something similar to humans, dinosaurs, frogs and eagles (although the details would certainly differ) would be seen if the process were allowed to keep to itself for a few billion years. This interpretation acquires even greater significance when applied to humans; would such an intelligent, successful and self-centered species as Homo sapiens have evolved in an alternative evolutionary universe?

There is a lot of interesting discussion to be had about this topic. It's equally fascinating when applied to chemistry and leads to similar questions. For instance, what are the chances that the foundational compounds of life - DNA, RNA, amino acids, sugars, ATP - would have formed had evolution been left to run again with different tweaks and quirks of fate? Personally I find the questions somewhat easier to answer in case of chemistry since the formation of many of these compounds is governed by relatively simple energetic arguments. ATP's express purpose is to make otherwise unfavorable reactions possible by driving them downhill through high-energy bonds, and if not ATP it's hard to see how some other chemical compounds performing the same function could not have evolved. A great example of an attempt to answer these questions is seen in Frank Westheimer's classic paper "Why Nature Chose Phosphates?" in which he points to the unique properties of phosphate that make it such a dominant source in life's workings, both in metabolism and heredity.

Breslow's question is therefore quite sensible and its implications are fascinating to ponder. How would 2012 have looked like had the dinosaurs not been wiped out by an asteroid? Would they still have been alive and would humans have had the unfortunate fate of co-existing with them? Would they be as smart as humans? Naturally such scenarios would have profoundly affected the evolution and character of our civilization. Or would the dinosaurs have precluded the rise of Homo sapiens, perhaps by nipping our scarce population in the bud and making us extinct? Or would they have become extinct themselves through some other cause, perhaps extreme climate change? How indeed would planet earth have looked like had it still been ruled by dinosaurs?

Naturally we don't know the answers to these questions. But Breslow's little joke at the end, while sounding silly, inadvertently asks a very important and thought-provoking question. Too bad it was all obscured by the charges of self-plagiarism.